Nyxoah to Participate in the 43rd Canaccord Genuity Growth Conference

Rhea-AI Summary

Nyxoah (NYXH) to Participate in Canaccord Genuity Growth Conference, CEO to Deliver Corporate Update on OSA Solutions

Positive

• Nyxoah's participation in the Canaccord Genuity 43rd Growth Conference indicates its proactive approach to investor engagement and potential business expansion opportunities.
• The webcast of the presentation and availability for 1x1 meetings with institutional investors demonstrate Nyxoah's commitment to transparency and investor relations, potentially boosting investor confidence.

Negative

• None.

Nyxoah to Participate in the 43rd Canaccord Genuity Growth Conference

Mont-Saint-Guibert, Belgium – July 27, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Canaccord Genuity 43^rd Growth Conference, which takes place August 7 – 10, 2023 in Boston, Massachusetts.

Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver a corporate update on Wednesday, August 9, 2023, at 9:30am EST. A webcast of the presentation will be available on the Events section of Nyxoah’s Investor Relations website. The Company will also be available for 1x1 meetings with institutional investors attending the event.

Nyxoah’s Investor Presentation can be accessed on the Shareholder Information section of the Company’s Investor Relations page.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

Attachment

• ENGLISH_Nyxoah to Participate in the 43rd Canaccord Genuity Growth Conference

FAQ

What is the Canaccord Genuity 43rd Growth Conference and when will Nyxoah participate?

The Canaccord Genuity 43rd Growth Conference is scheduled for August 7 – 10, 2023 in Boston, Massachusetts. Nyxoah will participate on August 9, 2023 at 9:30am EST.

Who will deliver the corporate update for Nyxoah at the conference?

Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver the corporate update on the Company's innovative solutions for Obstructive Sleep Apnea (OSA).

Where can investors access Nyxoah's Investor Presentation?

Nyxoah's Investor Presentation can be accessed on the Shareholder Information section of the Company’s Investor Relations page.